From: Prediction of resistance to chemotherapy in ovarian cancer: a systematic review
Study | Prediction | Classes | HR | 95% CI | Median survival | P value |
---|---|---|---|---|---|---|
Jeong et al. [22] | OS | YA subgroup vs. YI subgroup | 0.5 | 0.31−0.82 |  | 0.005 |
Roque et al. [24] | OS | High vs. low TUBB3 staining | 3.66 | 1.11−12.05 | 707 days vs. not reached | 0.03 |
Kang et al. [31] | OS | High vs. low score | 0.33 | 0.13−0.86 | 1.8 years vs. 2.9 years | <0.001 |
Skirnisdottir and Seidal [35] | Recurrence | p53 -ve vs. +ve | 4.12 | 1.41−12.03 |  | 0.009 |
Schlumbrecht et al. [40] | RFS | EIG121 high vs. low | 1.13 | 1.02−1.26 |  | 0.021 |
Yoshihara et al. [43] | PFS | High vs. low score | 1.64 | 1.27−2.13 |  | 0.0001 |
Denkert et al. [45] | OS | Low vs. high score | 1.7 | 1.1−2.6 |  | 0.021 |
Crijns et. al [47] | OS |  | 1.94 | 1.19−3.16 |  | 0.008 |
Netinatsunthorn et al. [51] | RFS | Yes vs. no WT1 staining | 3.36 | 1.60−7.03 |  | 0.0017 |
Spentzos et al. [54] | OS | Resistant vs. sensitive | 3.9 | 1.3−11.4 | 41 months vs. not reached | <0.001†|
Raspollini et al. [56] | OS | No vs. yes COX-2 staining | 0.23 | 0.06−0.77 |  | 0.017 |
Spentzos et al. [58] | OS | High vs. low score | 4.6 | 2.0−10.7 | 30 months vs. not reached | 0.0001 |